EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of novel regimens targeting oxidative phosphorylation in Mycobacterium tuberculosis

Dongshuo Li, Liang Li, Ye Zhang, Kai Cheng, Wenwen Liang, Eric Nuermberger iD, Xianglong Qi, Lei Fu, Bin Wang, Chenxia Yan, Rui Xu, Yu Lu iD und 1 weitere

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00019-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Dongshuo Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Oxidative Phosphorylation, Antitubercular Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Municipal Health Commission, National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycobacterium tuberculosis in both replicating and non-replicating states relies on oxidative phosphorylation (OxPhos) to generate ATP for its growth and survival. Our research delved into the efficacy of novel regimens targeting the OxPhos pathway in murine models. The combination of bedaquiline, clofazimine, pyrazinamide, alongside telacebec, and SQ109 was investigated against both wild-type M. tuberculosis H37Rv and an Rv0678 mutant with cross-resistance between bedaquiline and clofazimine. The results demonstrated that the combination regimens, particularly bedaquiline + clofazimine + pyrazinamide (BCZ) along with telacebec (BCZT) and SQ109 (BCZS), exhibit significantly enhanced bactericidal activity compared to bedaquiline alone and sterilizing potential against M. tuberculosis in vivo . Notably, the BCZT regimen showed superior activity compared to other treatment regimens in Rv0678 mutant-infected BALB/c mice. The addition of T to BCZ prevented the amplification of bedaquiline-resistant mutants and reduced the number of mice relapsing. Our finding underscores the potential of targeting the OxPhos pathway to combat M. tuberculosis , paving the way for innovative approaches in tuberculosis therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisOxidative PhosphorylationAntitubercular AgentsAnimalsDiarylquinolinesClofazimineMicePyrazinamideMice, Inbred BALB CMicrobial Sensitivity TestsFemaleDrug Therapy, CombinationImidazolesAdamantanePiperidinesEthylenediaminesPyridines

Stichwörter der Autor:innen

Mycobacterium tuberculosisbedaquilineclofazimineelectron transport chainmurine modeloxidative phosphorylationpyrazinamidetelacebec

Substanzen

Antitubercular AgentsbedaquilineDiarylquinolinesClofaziminePyrazinamidetelacebecN-geranyl-N'-(2-adamantyl)ethane-1,2-diamineImidazolesAdamantanePiperidines

Autor:innen und Institutionen

  • Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
  • Department of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

ORCID-Profile: Eric Nuermberger, Yu Lu, Jian Xu

Förderung

  • Beijing Municipal Health Commission
  • National Natural Science Foundation of China
  • Natural Science Foundation of Beijing Municipality
  • Beijing Hospital Authority

Zitieren

APA

Li, D., Li, L., Zhang, Y., Cheng, K., Liang, W., Nuermberger, E., Qi, X., Fu, L., Wang, B., Yan, C., Xu, R., Lu, Y., & Xu, J. (2025). Efficacy of novel regimens targeting oxidative phosphorylation in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00019-25

Vancouver

Li D, Li L, Zhang Y, Cheng K, Liang W, Nuermberger E, et al. Efficacy of novel regimens targeting oxidative phosphorylation in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00019-25

BibTeX
@article{Li2025,
  author = {Li, Dongshuo and Li, Liang and Zhang, Ye and Cheng, Kai and Liang, Wenwen and Nuermberger, Eric and Qi, Xianglong and Fu, Lei and Wang, Bin and Yan, Chenxia and Xu, Rui and Lu, Yu and Xu, Jian},
  title = {Efficacy of novel regimens targeting oxidative phosphorylation in Mycobacterium tuberculosis},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00019-25}
}
Kostenlos starten →